<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00886925</url>
  </required_header>
  <id_info>
    <org_study_id>ALFAE</org_study_id>
    <secondary_id>2008-003376-21</secondary_id>
    <secondary_id>PI07 - 0641</secondary_id>
    <nct_id>NCT00886925</nct_id>
  </id_info>
  <brief_title>Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis</brief_title>
  <acronym>ALFAE</acronym>
  <official_title>Effects of the Administration of Albumin in Patients With Cirrhosis and Acute Hepatic Encephalopathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the administration of albumin in addition
      to the standard care is effective in the treatment of an episode of hepatic encephalopathy in
      patients with cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatic encephalopathy is a frequent complication of cirrhosis that is usually associated
      with poor prognosis. The most common presentation is an acute episode of hepatic
      encephalopathy precipitated by factors that increase the exposure of the brain to ammonia.
      Current therapies are based on measures that decrease plasma ammonia and counteract the
      effect of factors such as infection or electrolyte's disturbances. Brain edema and
      abnormalities of cerebral blood flow appear to be important. Part of the impairment of
      astrocyte function could be related to an increase of oxidative stress injury.

      In patients with cirrhosis and hepatic encephalopathy, the concentration of albumin in plasma
      is usually low. Administration of human albumin in patients with hepatorenal syndrome and
      spontaneous bacterial peritonitis has a major impact on the prognosis of these complications.
      Albumin prevents circulatory dysfunction and renal failure. The mechanisms of action may
      include the maintenance of oncotic pressure and a scavenger effect of toxic substances
      present in blood. Albumin has also shown beneficial effects in neurological injury secondary
      to stroke, probably in relation to this scavenger effect.

      The administration of intravenous albumin to patients with hepatic encephalopathy may have
      beneficial effects on the course of encephalopathy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients without hepatic encephalopathy</measure>
    <time_frame>Day 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of encephalopathy assessed by CHESS and West-Haven</measure>
    <time_frame>Admission to the hospital (up to day 14)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Albumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin</intervention_name>
    <description>Albumin 20%. Day 0: 400-600 ml. Day 2: 200-400 ml.</description>
    <arm_group_label>Albumin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium chloride 0.9%</intervention_name>
    <description>Day 0: 400-600 ml. Day 2: 200-400 ml.</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cirrhosis of the liver

          -  Hepatic encephalopathy stage&gt;1

          -  Completion of a standardized protocol to investigate precipitating factors

          -  Informed consent by next of keen

        Exclusion Criteria:

          -  Pregnancy

          -  Terminal liver disease (advanced liver disease and performance status 3-4 prior to the
             episode of acute encephalopathy)

          -  Need of advanced life support (mechanical ventilation, ionotropic support, dialysis)

          -  Need of albumin administration (e.g. bacterial spontaneous peritonitis)

          -  Contraindication for albumin administration (e.g. cardiac failure)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Cordoba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2009</study_first_submitted>
  <study_first_submitted_qc>April 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2009</study_first_posted>
  <last_update_submitted>December 14, 2012</last_update_submitted>
  <last_update_submitted_qc>December 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic encephalopathy</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Albumin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

